Silence Therapeutics’ Divesiran Delivers Strong Phase 2 Results in Rare Blood Cancer, Setting Up Challenge to Takeda
Silence Therapeutics reports 88% response rate for divesiran in polycythemia vera Phase 2 trial. Quarterly dosing could challenge Takeda’s rusfertide.
